Ulcerative colitis is a long-term condition that causes inflammation and ulcers in the lining of the colon. Treatment focuses on controlling inflammation, managing flare-ups, and maintaining remission using different categories of medications depending on disease severity.

This guide explains the main ulcerative colitis medications, how they are used, typical dosages, side effects, and general cost expectations.

---

Overview of Ulcerative Colitis Medications

Treatment is usually step-based, meaning doctors start with safer, milder drugs and move to stronger therapies if needed.

Main medication categories include:

• Aminosalicylates (5-ASA drugs)
• Corticosteroids
• Immunomodulators
• Biologic therapies
• JAK inhibitors (advanced oral therapy)

Each category works differently to reduce inflammation in the colon.

---

1. Aminosalicylates (5-ASA drugs) Common medication:

Mesalamine

Uses:

• First-line treatment for mild to moderate ulcerative colitis
• Maintenance therapy to prevent relapse

How it works:

Reduces inflammation directly in the intestinal lining.

Dosage:

• Oral: typically 2.4 g–4.8 g per day (varies by product)
• Rectal forms: suppositories or enemas used daily or as prescribed

Side effects:

• Headache
• Nausea
• Abdominal discomfort (rare)
• Mild rash (uncommon)

Price range:

• Generally low to moderate cost
• Generic mesalamine is more affordable than branded versions

---

2. Corticosteroids (Flare control only) Common drugs:

• Prednisone
• Budesonide

Uses:

• Short-term treatment of moderate to severe flare-ups
• Rapid inflammation control

Important note:

Not used for long-term maintenance due to side effects.

Dosage:

• Prednisone: commonly 20–40 mg/day initially, then tapered
• Budesonide: often 9 mg/day in controlled-release form

Side effects:

• Weight gain
• Mood changes
• High blood sugar
• Bone thinning (with long-term use)
• Increased infection risk

Price range:

• Generally low cost for oral steroids

---

3. Immunomodulators Common medication:

Azathioprine

Uses:

• Maintenance therapy for moderate disease
• Reduces dependence on steroids

How it works:

Suppresses immune system activity to reduce chronic inflammation.

Dosage:

• Typically weight-based (around 1–2.5 mg/kg/day for azathioprine)

Side effects:

• Lowered white blood cell count
• Liver enzyme changes
• Increased infection risk
• Rare long-term cancer risk (very low but monitored)

Price range:

• Moderate cost, often generic and affordable

---

4. Biologic therapies Common drugs:

Infliximab
Adalimumab
Vedolizumab

Uses:

• Moderate to severe ulcerative colitis
• Patients not responding to standard therapy
• Long-term disease control

How they work:

Target specific immune pathways to reduce inflammation.

Dosage:

• Infliximab: IV infusion every 6–8 weeks after induction
• Adalimumab: self-injection every 2 weeks
• Vedolizumab: IV infusion every 8 weeks after induction

Side effects:

• Increased infection risk
• Injection or infusion reactions
• Fatigue
• Rare allergic responses

Price range:

• High cost (often the most expensive treatment class)
• Insurance coverage usually required

---

5. JAK inhibitors (Advanced oral therapy) Common drugs:

Tofacitinib
Upadacitinib

Uses:

• Moderate to severe ulcerative colitis
• When biologics are ineffective or not tolerated

How it works:

Blocks intracellular inflammatory signaling pathways.

Dosage:

• Tofacitinib: usually 10 mg twice daily (induction), then lower maintenance dose
• Upadacitinib: once-daily dosing depending on phase

Side effects:

• Increased cholesterol levels
• Risk of shingles
• Blood clot risk in susceptible patients
• Infections

Price range:

• High cost, similar to biologics
• Often requires prior authorization

---

General Price Overview (Important reality check)

Medication cost depends heavily on:

• Country and healthcare system
• Insurance coverage
• Generic vs branded versions
• Route of administration (oral vs infusion)

Typical cost pattern:

• 5-ASA drugs → low to moderate cost
• Steroids → low cost
• Immunomodulators → moderate cost
• Biologics → high cost (often thousands per month without insurance)
• JAK inhibitors → high cost

Key insight: In most healthcare systems, biologics and JAK inhibitors are the biggest financial burden without coverage support.

---

Side Effect Summary (Across all medications)

Common risks across treatments include:

• Infection susceptibility (immunosuppressive therapies)
• Gastrointestinal discomfort (milder drugs)
• Liver enzyme changes (some immunomodulators)
• Long-term immune suppression risks (advanced therapies)

---

Conclusion

Ulcerative colitis treatment is highly individualized and typically progresses from mild anti-inflammatory drugs to advanced immune-targeted therapies depending on disease severity. While early-stage treatments are relatively affordable and well tolerated, advanced therapies offer stronger disease control but come with higher cost and closer medical monitoring requirements.